In postmarketing reports, DPP-4 inhibitors have also been associated with hypersensitivity reactions, including anaphylaxis and angioedema, and are therefore contraindicated in patients with a history of hypersensitivity reactions. This evidence concerns the gene DPP4 and hypersensitivity reaction disease.